QT interval prolongation with Zytiga
Prolongation of the QT interval has been added as an adverse event with unknown frequency to the summary of product characteristics (SPC) for Zytiga (abiraterone; Janssen-Cilag). The updated SPC now advises caution when administering Zytiga with medicinal products known to prolong the QT interval or those able to induce torsade de pointes.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069051
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com